Disclosed are the ERK inhibitors of Formula (1.0) : and the pharmaceutically acceptable salts and solvates thereof.
所公开的是式(1.0)的ERK抑制剂；及其药学上可接受的盐和溶剂合物。
This invention relates to novel prostacyclin derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof.
本发明涉及新型的前列环素衍生物及其可接受的酸加成盐、溶剂化 物、水合物及多晶型物。
The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates.
本发明亦提供药学组合物，其包括化学式（4）的化合物、它们药学上可接受的盐类和溶剂化物。
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed.
本发明公开了沙利度胺及其药学可接受的前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed.
本发明公开了沙利度胺及其药学可接受的前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。
应用推荐